Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. News
  7. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
Delayed Nasdaq  -  04:00 2022-12-09 pm EST
16.51 USD   -4.68%
05:02pNOVAVAX INC Change in Directors or Principal Officers (form 8-K/A)
AQ
12/08French Public Health Body Snubs Valneva in COVID-19 Vaccine Strategy
MT
12/08Valneva shares fall as French health body advises against its COVID-19 vaccine
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novavax, Inc. Is Revises Revenue Guidance for Full Year 2022

08/09/2022 | 05:06pm EST

Novavax, Inc. is revising full year 2022 total revenue guidance to $2 billion to $2.3 billion. Total revenue reflects all sources, including product sales of Nuvaxovid by Novavax, grants revenue, royalties and other revenue.


ę S&P Capital IQ 2022
All news about NOVAVAX, INC.
05:02pNOVAVAX INC Change in Directors or Principal Officers (form 8-K/A)
AQ
12/08French Public Health Body Snubs Valneva in COVID-19 Vaccine Strategy
MT
12/08Valneva shares fall as French health body advises against its COVID-19 vaccine
RE
12/08Novavax's COVID-19 Jab Gets Canadian Approval for Adolescents
MT
12/07Novavax Covid-19 Vaccine Gets Health Canada Approval for Adolescents
DJ
12/07Novavax Says Canadian Regulator Approves Nuvaxovid COVID-19 Vaccine for Adolescents
MT
12/07Canada OKs Novavax's Covid Vaccine for Adolescents Aged 12-17
MT
12/07Novavax, Inc. Announces Nuvaxovid COVID-19 Vaccine Approval in Canada for Use as a Prim..
CI
12/07Novavax Nuvaxovid COVID-19 Vaccine Approved in Canada for Use as a Primary Series in Ad..
PR
12/07Transcript : Novavax, Inc. Presents at Bank of America 2022 Virtual Biotech S..
CI
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Financials (USD)
Sales 2022 2 011 M - -
Net income 2022 -565 M - -
Net cash 2022 1 455 M - -
P/E ratio 2022 -2,35x
Yield 2022 -
Capitalization 1 360 M 1 360 M -
EV / Sales 2022 -0,05x
EV / Sales 2023 -0,07x
Nbr of Employees 1 541
Free-Float 98,6%
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Last Close Price 17,32 $
Average target price 78,17 $
Spread / Average Target 351%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.-87.89%1 360
MODERNA, INC.-29.52%70 958
IQVIA HOLDINGS INC.-25.42%39 082
LONZA GROUP AG-39.99%36 246
ALNYLAM PHARMACEUTICALS, INC.36.41%29 282
SEAGEN INC.-18.99%23 253